Top Story

FOLFOXIRI plus bevacizumab improved outcomes, increased toxicity in metastatic colorectal cancer

October 22, 2014

Patients with metastatic colorectal cancer who received first-line treatment with bevacizumab plus FOLFOXIRI chemotherapy demonstrated significantly longer PFS than those treated with bevacizumab plus FOLFIRI chemotherapy, according to results of a randomized phase 3 study.

However, bevacizumab plus FOLFOXIRI was associated with higher rates of certain adverse events, results showed.

In the Journals

Risk-adjusted model reveals little variation in hospital readmissions after colorectal cancer surgery

October 22, 2014
Researchers who used a risk-adjusted model to evaluate readmission rates after colorectal cancer surgery found little variation between hospitals.The finding raises…
Meeting News Coverage

Incidence of small bowel tumors increased over the last decade

October 22, 2014
PHILADELPHIA — Small bowel tumor incidence rates have increased over the last decade among various ethnic groups, according to data presented at the ACG Annual…
Meeting News Coverage

Advanced histology in diminutive adenomas three-fold higher in CRC vs. screening patients

October 22, 2014
PHILADELPHIA — Advanced histology in lesions sized 9 mm or less occurred at a higher rate in patients with colorectal cancer compared with patients who underwent…
More News Headlines »
Case Challenges

A 54-year-old woman with bilateral hydronephrosis

HemOnc Today, August 25, 2014
Ramya Varadarajan, MD
A 54-year-old black woman presented to her primary care physician after experiencing worsening fatigue and abdominal…
More »
Meeting News Coverage Video
figure

Nomogram predicted recurrence risk among women who underwent APBI

September 26, 2014
Jessica Wobb, MD, senior resident in radiation oncology at Beaumont Health System in Birmingham, Mich., describes how…
More »